This CME/CMLE-accredited, case-based microlearning activity is designed to help laboratory team members increase their knowledge, skills, and competence in diagnosing various ILDs and making testing recommendations based on clinical practice guidelines, while also increasing their understanding of the signs, symptoms, and disease burden of interstitial lung diseases (ILDs). Every few days, several questions will be emailed or sent through the Qstream app, allowing learners to hone their diagnostic and decision-making skills in minutes each week.
This case-based microlearning activity includes the following topics: best practices in the interpretation of lung biopsy results in patients with ILDs, histologic findings that may indicate an alternate diagnosis, clinical practice guidelines for ILDs, the critical importance of multidisciplinary discussions in the diagnosis and management of patients with ILDs, ILD epidemiology, risk factors, comorbidities, and disease burden, and current antifibrotic treatment options for ILDs.
The activity offers 1.0 CME/CMLE credit.
Target Audience
This activity has been designed to meet the educational needs of members of the laboratory team (ie, pathologists, residents, fellows, and laboratory professionals including medical laboratory scientists/medical technologists) who are involved with the testing and diagnosis of ILDs such as IPF, other CF-ILDs with a progressive phenotype, SSc-ILD, and chILD.
Activity Agenda
- 21 case-based microlearning questions followed by detailed explanations
- Questions are delivered 3 at a time via email
Learning Objectives
Upon completion of this activity, you should be able to:
- Differentiate between ILDs and potential mimics in lung biopsies in cases involving patients with ILDs, utilizing patient data (eg, lung biopsy slides, clinical information)
- Recommend appropriate biopsy and serologic testing in cases involving patients with ILDs in accordance with clinical practice guidelines
- Differentiate between different subtypes of ILDs based on knowledge of the signs and symptoms, disease course, and disease burden of ILDs
Faculty
|
Sanjay Mukhopadhyay, MD |
Director of Pulmonary Pathology, Cleveland Clinic, Associate Editor (Pulmonary) for the American Journal of Clinical Pathology and Associate Editor (Social Media) for Modern Pathology |
|
Jefree J. Schulte, MD |
Assistant Professor, Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health |
|
Sara O. Vargas, MD |
Staff Pathologist, Director of Pulmonary Pathology, and Director of Quality and Patient Safety, Department of Pathology, Boston Children’s Hospital, Staff Pathologist, Brigham and Women’s Hospital, Associate Professor, Harvard Medical School |
Faculty Disclosures
|
Faculty |
Ineligible Company |
For what role? |
|
Sara O. Vargas, MD |
Vertex Pharmaceuticals |
Consultant |
|
Millipore Sigma |
Advisor |
All of the relevant financial relationships listed for Sara O. Vargas, MD have been mitigated
Sanjay Mukhopadhyay, MD and Jefree J. Schulte, MD have no relevant financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this online microlearning activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this online microlearning activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete all questions in the microlearning activity.
Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Provided by the American Society for Clinical Pathology.